
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PQGrass306
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PQGrass306 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : PQGrass306
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Details : VLP Peanut is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 27, 2022
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : holoBLG
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Ecarf Institute GmbH | Bencard Allergie GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of holoBLG on Cat Allergic Patients
Details : HoloBLG is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypersensitivity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : holoBLG
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Ecarf Institute GmbH | Bencard Allergie GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Lead Product(s) : VLP Peanut
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VLP-based Peanut Allergy Vaccine
Therapeutic Area : Immunology
Study Phase : IND Enabling
Recipient : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 31, 2022
Lead Product(s) : VLP-based Peanut Allergy Vaccine
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : AGC Biologics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PQGrass309
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Exploratory Study of PQ Grass 27600 SU
Details : PQGrass309 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 29, 2020
Lead Product(s) : PQGrass309
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.
Product Name : Grass MATA MPL
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tree MATA MPL
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Allergy Therapeutics Announces Invalidation of the Birch MATA MPL Phase III Primary Endpoint Results
Details : Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergen...
Product Name : Tree MATA MPL
Product Type : Vaccine
Upfront Cash : Inapplicable
July 09, 2020
Lead Product(s) : Tree MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Syneos Health | Metronomia Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
Details : Grass MATA MPL is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2019
Lead Product(s) : Grass MATA MPL
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Syneos Health | Metronomia Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Grass MATA MPL Extract
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Grass MATA MPL Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Grass MATA MPL Extract
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
